| Market Capitalization (Millions $) |
792 |
| Shares
Outstanding (Millions) |
96 |
| Employees |
154 |
| Revenues (TTM) (Millions $) |
169 |
| Net Income (TTM) (Millions $) |
-49 |
| Cash Flow (TTM) (Millions $) |
20 |
| Capital Exp. (TTM) (Millions $) |
0 |
Avadel Pharmaceuticals Plc
Avadel Pharmaceuticals Plc is a pharmaceutical company that develops, manufactures, and commercializes various drugs primarily for sleep disorders and other central nervous system conditions. The company's products are designed to improve the quality and duration of sleep, providing patients with better sleep management options.
Avadel develops both branded and generic drugs and has a diverse product portfolio. Its flagship drug, FT218, is an extended-release formulation of sodium oxybate, which is used to treat narcolepsy. The company also offers other medications such as Bloxiverz, Vazculep, and Akovaz, which are used in anesthesia and related procedures.
In addition to its focus on sleep disorders, Avadel Pharmaceuticals is actively exploring potential opportunities within the pediatric market and other therapeutic areas. The company is committed to innovation and research, continuously working on developing new drugs and improving existing formulations to better serve patients' needs.
Avadel Pharmaceuticals operates globally and collaborates with partners and distributors to ensure the efficient production, marketing, and distribution of its drugs. The company is headquartered in Dublin, Ireland, and is publicly traded on the NASDAQ stock exchange under the ticker symbol AVDL.
Company Address: 10 Earlsfort Terrace Dublin 2 0
Company Phone Number: 901-5201 Stock Exchange / Ticker: NASDAQ AVDL
|
0.99%